Eric Bradford

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Ian Pavord, Pascal Chanez, Gerard J. Criner et al. · New England Journal of Medicine · 2017 · 591 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

Geoffrey Chupp, Eric Bradford, Frank C. Albers et al. · The Lancet Respiratory Medicine · 2017 · 590 citations

Medicine, Pharmacology, Pharmacotherapy +14

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

Sumita Khatri, Wendy C. Moore, Peter G. Gibson et al. · Journal of Allergy and Clinical Immunology · 2018 · 300 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

Florence Roufosse, Jean‐Emmanuel Kahn, Marc E. Rothenberg et al. · Journal of Allergy and Clinical Immunology · 2020 · 202 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study

Sandhya Khurana, Guy Brusselle, Elisabeth H. Bel et al. · Clinical Therapeutics · 2019 · 166 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13